AAT 076

Drug Profile

AAT 076

Alternative Names: AAT-076; RQ-00317076

Latest Information Update: 24 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator RaQualia Pharma
  • Class Analgesics
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acute pain

Most Recent Events

  • 24 Feb 2016 Phase II development is ongoing in Japan
  • 01 Jan 2016 AAT 076 licensed to RMX Pharmaceutical Technology in China
  • 28 Dec 2011 RaQualia enters into a Letter of Intent with Chinese Academy of Sciences for licensing/co-development of RQ 00317076 for Acute pain and Lung cancer in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top